The BLOC1S2 Knockout A-549 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population in which the BLOC1S2 gene has been disrupted via CRISPR/Cas9-mediated gene disruption. This loss-of-function model provides a powerful tool for investigating the biological roles of BLOC1S2, a critical subunit of the biogenesis of lysosome-related organelles complex-1 (BLOC-1), in a human lung adenocarcinoma background. The polyclonal knockout format ensures a heterogeneous knockout population, enabling robust functional studies without the clonal selection bias inherent in monoclonal cell lines.
The host cell line A-549 is derived from a 58-year-old male with lung carcinoma and is widely employed as a model for human alveolar type II epithelium. These epithelial cells retain key characteristics of lung adenocarcinoma, including anchorage-independent growth and altered metabolic profiles, making them suitable for studying cancer cell biology, vesicular trafficking, and lysosomal function in a disease-relevant context. Their adherent monolayer growth facilitates high-resolution imaging and biochemical assays.
BLOC1S2 functions as an integral component of the BLOC-1 complex, which orchestrates the biogenesis of lysosome-related organelles by coordinating cargo sorting, vesicle transport, and fusion events. Mechanistically, BLOC1S2 interacts with a network of BLOC-1 subunits (BLOC1S1, BLOC1S3, BLOC1S4, BLOC1S5, BLOC1S6, DTNBP1, PLDN, MUTED, and CNO) and associates with the AP-3 complex, kinesin motor KIF13A, and SNARE protein SNAP-25. Its activity is regulated upstream by the transcription factor MITF and participates in downstream processes including melanosome cargo transport, lysosomal positioning, SNARE complex assembly, and apoptotic signaling pathways. Disruption of BLOC1S2 perturbs endosomal/lysosomal trafficking, potentially impairing autophagy and lysosomal degradation.
In A-549 cells, BLOC1S2 knockout is expected to compromise endolysosomal homeostasis, thereby affecting cellular processes such as autophagy flux, stress responses, and proliferation. This model provides a unique platform to dissect the role of the BLOC-1 complex in non-melanocytic cells, bridging the gap between classic melanosome biology and lung adenocarcinoma pathology. The dysregulation of lysosome-related trafficking may also influence cancer cell migration, invasion, and sensitivity to lysosomotropic agents, offering insights into tumor progression mechanisms.
This polyclonal knockout population is well-suited for a range of research applications, including modeling Hermansky-Pudlak syndrome cellular phenotypes, studying vesicle trafficking dynamics in lung adenocarcinoma, and exploring lysosomal dysfunction as a therapeutic vulnerability in cancer. Researchers can employ complementary assays such as immunofluorescence for LAMP1/LAMP2 to visualize lysosomal distribution, Lysotracker staining for lysosomal acidity, co-immunoprecipitation to assess BLOC-1 complex integrity, RT-qPCR for lysosomal gene expression profiling, and RNA-seq transcriptomic analysis. These applications support drug target validation and mechanistic investigations of endosomal/lysosomal pathways. For further information, please contact Ascent Research.
